Pillar 1 - FTO (new thread), page-978

@Titans19 that logic and reasoning is hard to argue with and very encouraging. Close to $450k spent on product manufacturing in the last 9 months (all after completion of the Israel trial) compared to $400k in the year to June 2020. That's a significant amount of money for a frugally run company to be spending without good reason...

I assume if there is such a program being run with Bisantrene there are very good reasons why it and any outcomes have not been formally announced to us, so for the time being we're left to draw our own conclusions.

However, @RaceOncology are you able to enlighten us on company obligations relating to disclosure of compassionate use programs in general? In particular, if these programs do not have to be announced or are not allowed to be announced to the market, how is price-sensitive information that may be gained through such use managed to ensure people involved (excluding company insiders of course) do not have an advantage with regards to trading in the securities of the company involved?

Thank you.